Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Naldini

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Physiological Research|January 1, 1993
The lymphatic route. IX. Distribution of recombinant interferon-alpha 2 administered subcutaneously with oedematogenic drugsG P Pessina, V Bocci, F Carraro, et al.
General Pharmacology|March 13, 2002
Thrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1A Naldini, D H Carney, A Pucci, et al.
General Pharmacology|January 1, 1987
Studies on tumor necrosis factor (TNF)--I. Pharmacokinetics of human recombinant TNF in rabbits and monkeys after intravenous administrationV Bocci, A Pacini, G P Pessina, et al.
Lymphokine Research|January 1, 1987
Studies on tumor necrosis factor (TNF): II. Metabolic fate and distribution of human recombinant TNFG P Pessina, A Pacini, V Bocci, et al.
Journal of Cellular Physiology|September 10, 1998
Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiationA Naldini, L Sower, V Bocci, et al.
Oncology|November 24, 2004
Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?D Lorusso, A Naldini, A Testa, et al.
Experientia|April 15, 1986
The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasmaV Bocci, M Muscettola, G Grasso, et al.
Gynecologic Oncology|April 7, 2009
Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot studyA Fagotti, I Paris, F Grimolizzi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1987
Interleukin 2 inhibits in vitro granulocyte-macrophage colony formationA Naldini, W R Fleischmann, Z K Ballas, et al.
Gynecologic Oncology|October 18, 2005
Endometrioid adenocarcinoma with squamous differentiation arising from ureteral endometriosis in a patient with no history of gonadal endometriosisM G Salerno, V Masciullo, A Naldini, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Physiological Research|January 1, 1993
The lymphatic route. IX. Distribution of recombinant interferon-alpha 2 administered subcutaneously with oedematogenic drugsG P Pessina, V Bocci, F Carraro, et al.
General Pharmacology|March 13, 2002
Thrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1A Naldini, D H Carney, A Pucci, et al.
General Pharmacology|January 1, 1987
Studies on tumor necrosis factor (TNF)--I. Pharmacokinetics of human recombinant TNF in rabbits and monkeys after intravenous administrationV Bocci, A Pacini, G P Pessina, et al.
Lymphokine Research|January 1, 1987
Studies on tumor necrosis factor (TNF): II. Metabolic fate and distribution of human recombinant TNFG P Pessina, A Pacini, V Bocci, et al.
Journal of Cellular Physiology|September 10, 1998
Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiationA Naldini, L Sower, V Bocci, et al.
Oncology|November 24, 2004
Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?D Lorusso, A Naldini, A Testa, et al.
Experientia|April 15, 1986
The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasmaV Bocci, M Muscettola, G Grasso, et al.
Gynecologic Oncology|April 7, 2009
Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot studyA Fagotti, I Paris, F Grimolizzi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 1987
Interleukin 2 inhibits in vitro granulocyte-macrophage colony formationA Naldini, W R Fleischmann, Z K Ballas, et al.
Gynecologic Oncology|October 18, 2005
Endometrioid adenocarcinoma with squamous differentiation arising from ureteral endometriosis in a patient with no history of gonadal endometriosisM G Salerno, V Masciullo, A Naldini, et al.
Pageof 5